

## References

### L-5084

1. Bendtzen K. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. *Discov Med.* Apr 2013;15(83):201-211. PMID 23636137.
2. Kopylov U, Mazor Y, Yavzori M, et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. *Inflamm Bowel Dis.* Sep 2012;18(9):1628-1633. PMID 22038899.
3. White CM, Ip S, McPheeters M, et al. Using Existing Systematic Reviews to Replace De Novo Processes in Conducting Comparative Effectiveness Reviews Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2008.
4. Meroni PL, Valentini G, Ayala F, et al. New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis. *Autoimmun Rev.* Sep 2015;14(9):812-829. PMID 25985765.
5. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. *Ann Rheum Dis.* Dec 2013;72(12):1947-1955. PMID 23223420.
6. Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. *Eur J Gastroenterol Hepatol.* May 27 2012;24(9):1078-1085. PMID 22647738.
7. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in individuals with inflammatory bowel disease (IBD): a meta-analysis. *Am J Gastroenterol.* Jan 2013;108(1):40-47; quiz 48. PMID 23147525.
8. Thomas SS, Borazan N, Barroso N, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. a systematic review and meta-analysis. *BioDrugs.* Aug 2015;29(4):241-258. PMID 26280210.
9. Pecoraro V, De Santis E, Melegari A, et al. The impact of immunogenicity of TNFalpha inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis. *Autoimmun Rev.* Jun 2017;16(6):564-575. PMID 28411169.

10. Cludts I, Spinelli FR, Morello F, et al. Anti-therapeutic antibodies and their clinical impact in individuals treated with the TNF antagonist adalimumab. *Cytokine*. Aug 2017;96:16-23. PMID 28279855.
11. Ara-Martin M, Pinto PH, Pascual-Salcedo D. Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study. *J Dermatolog Treat*. Nov 2017;28(7):606- 612. PMID 28274164.
12. Lombardi G, Perego S, Sansoni V, et al. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence. *BMJ Open*. Dec 09 2016;6(12):e011941. PMID 27940624.
13. Arstikyte I, Kapleryte G, Butrimiene I, et al. Influence of immunogenicity on the efficacy of long-term treatment with TNF alpha blockers in rheumatoid arthritis and spondyloarthritis individuals. *Biomed Res Int*. Jun 2015;2015:604872. PMID 26064930.
14. van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum*. Jan 1996;39(1):34-40. PMID 8546736.
15. Castillo-Gallego C, Aydin SZ, Marzo-Ortega H. Clinical utility of the new ASAS criteria for spondyloarthritis and the disease activity score. *Curr Rheumatol Rep*. Oct 2011;13(5):395-401. PMID 21748416.
16. Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. *Arthritis Rheumatol*. May 2015;67(8):2011-2019. PMID 26109489.
17. Frederiksen MT, Ainsworth MA, Brynskov J, et al. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. *Inflamm Bowel Dis*. Oct 2014;20(10):1714-1721. PMID 25069030.
18. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. *Am J Gastroenterol*. Jun 2013;108(6):962-971. PMID 23419382.
19. Eser A, Primas C, Reinisch W. Drug monitoring of biologics in inflammatory bowel disease. *Curr Opin Gastroenterol*. Jul 2013;29(4):391-396. PMID 23703367.
20. Khanna R, Sattin BD, Afif W, et al. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. *Aliment Pharmacol Ther*. Sep 2013;38(5):447-459. PMID 23848220.

21. Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. *Therap Adv Gastroenterol*. Jul 2013;6(4):269-293. PMID 23814608.
22. Garces S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of individuals with RA receiving tumour necrosis factor inhibitor therapies. *Ann Rheum Dis*. Jun 2014;73(6):1138-1143. PMID 23666932.
23. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in individuals with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. *Gut*. Jun 2014;63(6):919-927. PMID 23878167.
24. Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. *Scand J Gastroenterol*. Mar 2011;46(3):310-318. PMID 21087119.
25. Tan M. Importance of defining loss of response before therapeutic drug monitoring. *Gut*. Mar 2015;64(3):516- 517. PMID 25031226.
26. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. *Am J Gastroenterol*. Aug 2014;109(8):1250-1256. PMID 24913041.
27. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in individuals with inflammatory bowel diseases. *Clin Gastroenterol Hepatol*. Jan 2014;12(1):80-84 e82. PMID 23891927.
28. Afif W, Loftus EV, Jr., Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in individuals with inflammatory bowel disease. *Am J Gastroenterol*. May 2010;105(5):1133-1139. PMID 20145610.
29. Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease. *Gastroenterology*. Sep 2017;153(3):827-834. PMID 28780013.
30. National Institute for Health and Care Excellence (NICE). Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) [DG22]. 2016; <https://www.nice.org.uk/guidance/dg22/chapter/1-Recommendations>. Accessed October 7, 2019.